Effects of cyclosporine in recent-onset juvenile type 1 diabetes: impact of age and duration of disease
- PMID: 3316581
- DOI: 10.1016/s0022-3476(87)80058-6
Effects of cyclosporine in recent-onset juvenile type 1 diabetes: impact of age and duration of disease
Abstract
Administration of cyclosporine resulted in reduced insulin requirements and improved glycemic control in patients with insulin-dependent diabetes mellitus of recent onset, but the drug was less effective in young children. Renal toxic effects and other problems related to therapy resolved after discontinuation of the drug. Sustained remission seemed dependent on continued administration of cyclosporine. Although short-term control of diabetes may be achieved in some patients, more studies are needed to determine whether cyclosporine can be given safely as maintenance therapy to maintain glycemic control and prevent the long-term consequences of the disease.
Similar articles
-
Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset.Science. 1984 Mar 30;223(4643):1362-7. doi: 10.1126/science.6367043. Science. 1984. PMID: 6367043
-
Induction and pathophysiology of remission of insulin-dependent diabetes mellitus during administration of ciclosporin. London Diabetes Study Group.Horm Res. 1990;33(2-4):152-8. doi: 10.1159/000181499. Horm Res. 1990. PMID: 2210620 Review.
-
Functional consequences and risk factors of chronic cyclosporine nephrotoxicity in type I diabetes trials.Transplant Proc. 1988 Jun;20(3 Suppl 4):356-66. Transplant Proc. 1988. PMID: 3381298 No abstract available.
-
Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin.Diabetes. 1990 Oct;39(10):1264-72. doi: 10.2337/diab.39.10.1264. Diabetes. 1990. PMID: 2210078
-
Cyclosporine in insulin-dependent diabetes mellitus.J Pediatr. 1987 Dec;111(6 Pt 2):1073-4. doi: 10.1016/s0022-3476(87)80059-8. J Pediatr. 1987. PMID: 3316582 Review. No abstract available.
Cited by
-
The challenge of modulating β-cell autoimmunity in type 1 diabetes.Lancet Diabetes Endocrinol. 2019 Jan;7(1):52-64. doi: 10.1016/S2213-8587(18)30112-8. Epub 2018 Oct 24. Lancet Diabetes Endocrinol. 2019. PMID: 30528099 Free PMC article. Review.
-
Cyclosporine pharmacokinetics and effect in the type I diabetic rat model.Eur J Drug Metab Pharmacokinet. 1989 Oct-Dec;14(4):287-92. doi: 10.1007/BF03190113. Eur J Drug Metab Pharmacokinet. 1989. PMID: 2699289
-
Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases.Int J Mol Sci. 2021 Mar 10;22(6):2805. doi: 10.3390/ijms22062805. Int J Mol Sci. 2021. PMID: 33802091 Free PMC article. Review.
-
Cyclosporin A treatment of young children with newly-diagnosed type 1 (insulin-dependent) diabetes mellitus. London Diabetes Study Group.Diabetologia. 1992 Sep;35(9):884-8. doi: 10.1007/BF00399937. Diabetologia. 1992. PMID: 1397785
-
Leverage biomaterials to modulate immunity for type 1 diabetes.Front Immunol. 2022 Nov 2;13:997287. doi: 10.3389/fimmu.2022.997287. eCollection 2022. Front Immunol. 2022. PMID: 36405706 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical